Main Conference Day 2 (29th April 2026) - CET/CEST (Cent Europe Summer, GMT+2)
- Lekan Daramola - Consultant, LD BioConsulting Limited
Maximising correct heterodimer assembly by synergy between viral vector engineering & host cell engineering
Implementation of advanced analytical strategies in early screening process
Enabling clone selection based on quality attributes, not just titre
Increasing final yield of correctly formed bi-specific antibody
- Preethi Krishnaraj - Post.Doc, Boehringer Ingelheim
- Michael Butler - Principal Investigator, Cell Technology, NIBRT
- Bhagya Yatipanthalawa - Research Fellow, The University of Melbourne / ARC Digital Bioprocess Development Hub
- Ernest Šprager - Expert Science & Technology, DSPD, Novartis Technical Research & Development
- Johannes Buyel - Head of Department, BOKU, Austria
Identifying CQAs for complex therapies with multiple mechanisms of action
Creating a comprehensive and representative potency profile with a combination of methods
Cytokine release, in vitro cytotoxicity, cell migration, etc.
Practical challenges of transferring and validation, from lab to QC
Profiling critical process-related impurities: Discussing the impact of empty/full capsids, aggregates, host cell proteins, and host cell DNA on product safety and efficacy.
Evaluating advanced analytical techniques for comprehensive impurity characterisation
Utilising analytics to drive process improvement:
Significantly improving full/empty capsid ratio
Developing an integrated control strategy throughout manufacturing process
Have a Solution for This Challenge?
This session is your platform to demonstrate leadership and technical expertise. Present your data, case studies, and innovative solutions to a targeted audience of senior scientists and engineers looking to solve hurdles in their production processes.
To learn more about sponsoring this session, contact us at Partners@informaconnectls.com
Full Abstract TBC
- Ignasi Bofarull-Manzano - Industrial PhD Candidate, CMC Data Scientist and Consultant, RWTH Aachen University
- Moo Sun Hong - Assistant Professor, Seoul National University
- Lekan Daramola - Consultant, LD BioConsulting Limited
Can transient expression in plants provide a method for rapid, scalable production of complex proteins?
Overcoming historical challenges associated with plant-based systems:
Differences in glycoform patterns
Downstream complexities
Advantages in scalability, cost, & safety with plant-based systems
Cell-free protein synthesis as an alternative to stable cell line development: dramatically reducing production timelines
Applications of this approach to provide a transformative advantage:
Rapid screening
Production of proteins toxic to living cells
Future of cell-free systems: scaling, production of therapeutic-grade material
Implementation of N-1 perfusion to reduce production cycle times, improve consistency, and reach higher final titres
Inoculating bioreactor at very high cell density
Overcoming N-1 perfusion hurdles:
Cell retention device selection
Process control strategy
Developing a robust strategy to implement N-1 perfusion successfully into existing workflows
Can the implementation of an integrated continuous manufacturing process achieve transformative volume of production?
Improving final product quality through reduced residence in continuous bioreactor
Overcoming high media consumption costs through innovative strategies
Dynamic perfusion rate control
Media recycling
Scalability of continuous facility: factory of the future?
- Sebastian Schwaminger - Associate Professor, Medical University of Graz
- Ernest Šprager - Expert Science & Technology, DSPD, Novartis Technical Research & Development
- Subash Ramamoorthy - Principal Automation & Robotics, Bayer AG
- Volker Huppert - Chief Development Officer, Glycostem Therapeutics
- Christian Witz - CEO, SimVantage GmbH
- A Representative from Johnson & Johnson Innovative Medicine - (Pending Final Confirmation), Johnson & Johnson Innovative Medicine
Overcoming the limitations of industry-standard triple-transient transfection for large scale AAV manufacturing:
Cost, scalability, batch to batch variability
Developing a stable, suspension-adapted inducible producer cell line (e.g. HEK293 or CHO-based host)
Vector design, clone selection, process optimisation
Improving full-to-empty capsid ratio and process scalability with innovative CLD approaches
Optimising critical process parameters (CPPs) such as media composition, feed strategy, etc. for maximal vector yield
Characterising impact of bioreactor shear stress on cell health and viral particle quality
Process comparability and scalability from bench-scale to pilot-scale single-use bioreactors
High-tire upstream processes can create a huge challenge for clarification:
Next generation clarification technologies for high-density harvests
Comparison of different approaches:
Data on efficiency and scalability
- Gearóid Duane - Senior Principal Scientist, Bristol Myers Squibb, Cruiserath Biologics
High-tire upstream processes can create a huge challenge for clarification:
Next generation clarification technologies for high-density harvests
Comparison of different approaches:
Data on efficiency and scalability
- Gearóid Duane - Senior Principal Scientist, Bristol Myers Squibb, Cruiserath Biologics
- Andy Wiranata Wijaya - Bioprocess Development Lead, Nestlé Product Technology Center
- Terri Gaskell (Pending Final Confirmation) - CTO, Rinri Therapeutics
The ‘smart factory’ requires a smart workforce
Overcoming the digital skills gap in biomanufacturing:
Effective training strategies
Role of VR in operator training
Building a culture of continuous learning
Upskilling existing teams
Overall supporting digital transformation
- Steven Fuller - Founder & Director, Race in STEM